이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

bluebird bio 관리

관리 기준 확인 3/4

bluebird bio's CEO는 Andrew Obenshain, Jan2021 에 임명되었습니다 의 임기는 3.42 년입니다. 총 연간 보상은 $ 1.81M, 35.5% 로 구성됩니다. 35.5% 급여 및 64.5% 보너스(회사 주식 및 옵션 포함). 는 $ 149.27K 가치에 해당하는 회사 주식의 0.085% 직접 소유합니다. 149.27K. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 13.3 년입니다.

주요 정보

Andrew Obenshain

최고 경영자

US$1.8m

총 보상

CEO 급여 비율	35.5%
CEO 임기	3.4yrs
CEO 소유권	0.09%
경영진 평균 재임 기간	1.8yrs
이사회 평균 재임 기간	13.3yrs

최근 관리 업데이트

Recent updates

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Jul 13

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Oct 04

Bluebird bio names interim finance chief

Sep 26

Bluebird bio jumps 17% on FDA approval of new gene therapy

Sep 19

bluebird bio' chief strategy and financial officer to depart

Sep 12

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

Aug 17

bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case

Jun 22

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential

May 09

Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet Approval

Feb 07

bluebird bio: Ticker Fueled By Gambling Chance Of Commercial Success

Dec 12

CEO 보상 분석

Andrew Obenshain 의 보수는 bluebird bio 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2023	n/a	n/a	-US$91m
Jun 30 2023	n/a	n/a	-US$96m
Mar 31 2023	n/a	n/a	-US$123m
Dec 31 2022	US$2m	US$643k	-US$267m
Sep 30 2022	n/a	n/a	-US$431m
Jun 30 2022	n/a	n/a	-US$507m
Mar 31 2022	n/a	n/a	-US$563m
Dec 31 2021	US$9m	US$486k	-US$563m

보상 대 시장: Andrew 의 총 보상 ($USD 1.81M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 1.62M ).

보상과 수익: Andrew 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Andrew Obenshain (50 yo)

3.4yrs

테뉴어

US$1,814,700

보상

Mr. Andrew Obenshain has been the Chief Executive Officer and Director of bluebird bio, Inc. since 2021 and serves as its President. He served as President of Severe Genetic Diseases since October 2020 unt...

리더십 팀

이름	위치	테뉴어	보상	소유권
Andrew Obenshain	President	3.4yrs	US$1.81m	0.085% $ 149.3k
Thomas Klima	Chief Commercial Officer & COO	1.8yrs	US$1.25m	0.063% $ 110.2k
Richard Colvin	Chief Medical Officer	3.3yrs	US$1.36m	0.023% $ 39.6k
Oliver Sterling	CFO & Principal Accounting Officer	no data	데이터 없음	데이터 없음
Joseph Vittiglio	Chief Legal & Business Officer and Secretary	1.4yrs	데이터 없음	0.0038% $ 6.6k
Jess Rowlands	Head of Corporate Communications	1.5yrs	데이터 없음	데이터 없음
Andrea Walton	Chief People Officer	2.4yrs	데이터 없음	데이터 없음
Kasra Kasraian	Senior Vice President of Technical Development & Operations	no data	데이터 없음	데이터 없음
Scott Shoemaker	Senior Vice President of Quality	3.4yrs	데이터 없음	데이터 없음
Sarah Alspach	Senior Vice President of External Affairs	1.5yrs	데이터 없음	데이터 없음
Jessica Whitten	VP & Global Controller	no data	데이터 없음	데이터 없음
Courtney O'Leary	Investor Relations Officer	no data	데이터 없음	데이터 없음

1.8yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: BLUE 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Andrew Obenshain	President	3.4yrs	US$1.81m	0.085% $ 149.3k
Philip Reilly	Member of Scientific Advisory Board	13.3yrs	데이터 없음	데이터 없음
Philippe Leboulch	Co-Chair of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Stephen Goff	Member of Scientific Advisory Board	13.3yrs	데이터 없음	데이터 없음
Mark Vachon	Independent Chairman	9.9yrs	US$142.23k	0.0074% $ 13.0k
Mitchell Finer	Member of Scientific Advisory Board	8.9yrs	US$1.57m	데이터 없음
Malcolm Brenner	Member of Scientific Advisory Board	13.3yrs	데이터 없음	데이터 없음
Christof von Kalle	Member of Scientific Advisory Board	13.3yrs	데이터 없음	데이터 없음
John Agwunobi	Independent Director	7yrs	US$91.31k	0.0081% $ 14.3k
Nick Leschly	Director	14.3yrs	US$27.31k	0.23% $ 408.7k
R. Humphries	Member of Scientific Advisory Board	13.3yrs	데이터 없음	데이터 없음
Elisabeth Leiderman	Independent Director	2.6yrs	US$97.81k	0.0043% $ 7.6k

13.3yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: BLUE 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 13.3 년).

bluebird bio 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

President recently sold US$60k worth of stock

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

Less than half of directors are independent

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

Recent updates

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio Is Priced Below IP Value

Price target increased by 8.0% to US$5.00

Bluebird Bio: Innovative Therapies, Monetary Setbacks

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Consensus revenue estimates fall by 13%

Price target decreased by 8.2% to US$6.61

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 31% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

Now 24% undervalued after recent price drop

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

New minor risk - Insider selling

President recently sold US$60k worth of stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

Consensus revenue estimates decrease by 26%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Consensus forecasts updated

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Bluebird bio names interim finance chief

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

Bluebird bio jumps 17% on FDA approval of new gene therapy

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

bluebird bio' chief strategy and financial officer to depart

Treasurer recently sold US$78k worth of stock

Consensus forecasts updated

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

President recently sold US$96k worth of stock

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased to US$8.22

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

Chief Regulatory Officer recently sold US$6.7k worth of stock

bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case

Consensus forecasts updated

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet Approval

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

CEO & Director recently sold US$74k worth of stock